Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.63 |
| ▸ | DRD2 | P14416 | 9/20 | 0.51 |
| ▸ | DRD3 | P35462 | 9/20 | 0.51 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271820 | 0.89 | HRH4 (0.49) | HRH4DRD2DRD3PARP1 | |
| SCHEMBL12271953 | 0.88 | HRH4 (0.48) | HRH4DRD2DRD3PARP1 | |
| SCHEMBL12271795 | 0.88 | DRD2 (0.51) | HRH4DRD2DRD3PARP1PDE10A | |
| SCHEMBL12271903 | 0.88 | PDE10A (0.54) | HRH4DRD2DRD3PARP1PDE10A | |
| SCHEMBL12271606 | 0.88 | HRH4 (0.63) | HRH4DRD2DRD3PARP1PDE10A | |
| SCHEMBL12271811 | 0.87 | HRH4 (0.46) | HRH4DRD2DRD3PARP1PARP2 | |
| SCHEMBL12271814 | 0.87 | HRH4 (0.50) | HRH4DRD2DRD3PARP1 | |
| SCHEMBL12272026 | 0.86 | HRH4 (0.48) | HRH4DRD2DRD3PARP1PDE10A | |
| SCHEMBL12271931 | 0.85 | HRH4 (0.63) | HRH4DRD2DRD3PARP1 | |
| SCHEMBL2238492 | 0.84 | DRD2 (0.55) | HRH4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2351749-A1 | CARBAMATE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351749-A1 | CARBAMATE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212973-A1 | CARBAMATE COMPOUND OR SALT THEREOF | FAAH, FAAH2, TRPV1 | HRH4 46/4885DRD2 3283/4885DRD3 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.